Clinical Trial Search

Primary: Time to Recovery From Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog) After Missed Meal Bolus — 1.79; 2.55 Hours — p=0.1450

Primary: Percentage of Participants Who Died — 0; 0; 0; 0 percentage of participants

Primary: Number of Participants With Local and Systemic Adverse Events in Year One — 39; 27; 19; 11 Participants

Primary: Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid…

Primary: To Evaluate the Feasibility of 1RG-CART Therapy in Patients With Relapsed or Refractory Neuroblastoma — 0; 0; 0; 0 Participants

Primary: Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab — 1; 1 Participants

Primary: Plasma Concentration of Tenofovir (TFV) — 0; 0; 0; 0 ng/mL

Primary: Maximum Observed Plasma Concentration (Cmax) of Racemic-Praziquantel (Rac-PZQ) — 421; 415; 425; 459 nanogram per milliliter (ng/mL)

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants

Primary: Maximum Reactogenicity Per Subject and Treatment Group — 5; 12; 9; 11 Participants

Primary: Area Under the Curve to From Time Zero to Infinity (AUC_∞) — 286.396; 493.808; 816.465 min*ng/mL

Primary: Incidence of Treatment-emergent Adverse Events Including Treatment-emergent Serious Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE)…

Primary: Percentage of Participants With Adverse Events (AEs) — 80.0; 75.0; 50.0; 83.3 Percentage of Participants

Primary: Change in Screening Metrics — 42; 8; 37; 13 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of Apremilast — 323; 274; 215 ng/mL